Compare AMBO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBO | CANF |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.0M |
| IPO Year | 2010 | 2011 |
| Metric | AMBO | CANF |
|---|---|---|
| Price | $1.98 | $3.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 5.7K | ★ 97.9K |
| Earning Date | 08-05-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 337.04 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $9,469,000.00 | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | $286.49 | ★ N/A |
| Revenue Growth | ★ 0.82 | N/A |
| 52 Week Low | $1.47 | $0.17 |
| 52 Week High | $6.75 | $10.40 |
| Indicator | AMBO | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 49.56 |
| Support Level | $2.01 | $3.18 |
| Resistance Level | $2.55 | $3.60 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 45.24 | 27.38 |
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.